

Annette Bruchfeld

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7062567/annette-bruchfeld-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

99
papers

4,097
citations

30
h-index

63
g-index

114
ext. papers

4,985
ext. citations

5.5
avg, IF

5.52
L-index

#	Paper	IF	Citations
99	C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study.. <i>CKJ: Clinical Kidney Journal</i> , 2022 , 15, 922-928	4.5	1
98	Pentraxin-3 - a potential biomarker in ANCA-associated vasculitis.. <i>Scandinavian Journal of Rheumatology</i> , 2022 , 1-9	1.9	0
97	COVID-19 in Patients with Glomerular Disease: Follow-Up Results from the IRoc-GN International Registry.. <i>Kidney360</i> , 2022 , 3, 293-306	1.8	1
96	The COVID-19 pandemic and ANCA-associated vasculitis - reports from the EUVAS meeting and EUVAS education forum. <i>Autoimmunity Reviews</i> , 2021 , 20, 102986	13.6	5
95	A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 23-35	4.5	3
94	Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	25
93	Acute kidney injury and mortality risk in older adults with COVID-19. <i>Journal of Nephrology</i> , 2021 , 34, 295-304	4.8	9
92	Nomenclature in nephrology: preserving RenalRand R nephroRin the glossary of kidney health and disease. <i>Journal of Nephrology</i> , 2021 , 34, 639-648	4.8	2
91	Rituximab in Membranous Nephropathy. <i>Kidney International Reports</i> , 2021 , 6, 881-893	4.1	9
90	POS1230 OUTCOME FOLLOWING COVID-19 INFECTION IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 898.2-898	2.4	
89	COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 1758-1760	4.3	9
88	OP0003 AUTOREACTIVE CD4+ T CELLS AND THEIR TCR REPERTOIRE IN PR3-ANCA ASSOCIATED VASCULITIS. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1.3-1	2.4	
87	MO358ACUTE KIDNEY INJURY AND MORTALITY RISK IN OLDER ADULTS WITH AND WITHOUT COVID-19: DATA FROM GEROCOVID STUDY. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36,	4.3	78
86	Effective cholesterol lowering after myocardial infarction in patients with nephrotic syndrome may require a multi-pharmacological approach: a case report. <i>European Heart Journal - Case Reports</i> , 2021 , 5, ytab151	0.9	0
85	The COVID-19 pandemic: consequences for nephrology. <i>Nature Reviews Nephrology</i> , 2021 , 17, 81-82	14.9	28
84	Rituximab in minimal change disease and focal segmental glomerulosclerosis. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 983-985	4.3	6
83	Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	4

82	Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	7
81	Albuminuria as a risk factor for mild cognitive impairment and dementia-what is the evidence?. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	3
80	The COVID-19 Epidemic: Management and Outcomes of Hemodialysis and Peritoneal Dialysis Patients in Stockholm, Sweden. <i>Kidney and Blood Pressure Research</i> , 2021 , 46, 250-256	3.1	2
79	COVID-19 vaccines and kidney disease. <i>Nature Reviews Nephrology</i> , 2021 , 17, 291-293	14.9	50
78	First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis. <i>Arthritis Research and Therapy</i> , 2021 , 23, 211	5.7	3
77	Observational study of risk factors associated with clinical outcome among elderly kidney transplant recipients in Sweden - a decade of follow-up. <i>Transplant International</i> , 2021 , 34, 2363-2370	3	1
76	Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	4
75	Brain dysfunction in tubular and tubulointerstitial kidney diseases. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	2
74	Mild cognitive impairment and kidney disease: clinical aspects. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 10-17	4.3	21
73	The cholinergic anti-inflammatory pathway in chronic kidney disease-review and vagus nerve stimulation clinical pilot study. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 1840-1852	4.3	5
72	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1243-1249	2.4	22
71	Is There Decreasing Public Interest in Renal Transplantation? A Google Trends Analysis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	1
70	The nephrology crystal ball: the medium-term future. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 222-236	4.3	2
69	Hepatitis C virus infection and global kidney health: the consensus proceedings of the International Federation of Kidney Foundations. <i>African Journal of Nephrology</i> , 2020 , 23, 159-168	0.8	
68	Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 920-925	4.3	7
67	Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. <i>Liver International</i> , 2020 , 40, 1032-1041	7.9	23
66	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. <i>Autoimmunity Reviews</i> , 2020 , 19, 102671	13.6	13
65	Venous thromboembolism in anti-neutrophil cytoplasmic antibody-associated vasculitis: an underlying prothrombotic condition?. <i>Rheumatology Advances in Practice</i> , 2020 , 4, rkaa056	1.1	1

64	Microparticles expressing myeloperoxidase as potential biomarkers in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). <i>Journal of Molecular Medicine</i> , 2020 , 98, 1279-1286	5.5	4
63	HCV eradication in chronic kidney disease: ready for prime time?. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 880-882	18.8	0
62	Funding kidney research as a public health priority: challenges and opportunities. <i>Nephrology Dialysis Transplantation</i> , 2020 ,	4.3	5
61	Novel insights into the disease transcriptome of human diabetic glomeruli and tubulointerstitium. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 2059-2072	4.3	9
60	Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2020 , 47, 580-588	4.1	2
59	Microparticles Expressing Myeloperoxidase and Complement C3a and C5a as Markers of Renal Involvement in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2020 , 47, 714-721	4.1	8
58	Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 1469-1480	4.3	5
57	019. PENTRAXIN-3 PLASMA LEVELS AND GENE POLYMORPHISMS IN ANCA-ASSOCIATED VASCULITIS. <i>Rheumatology</i> , 2019 , 58,	3.9	1
56	Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 1112-1114	4.3	19
55	The cholinergic anti-inflammatory pathway in resistant hypertension treated with renal denervation. <i>Molecular Medicine</i> , 2019 , 25, 39	6.2	6
54	Direct acting anti-viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease. <i>Seminars in Dialysis</i> , 2019 , 32, 135-140	2.5	3
53	Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 399-405	2.4	102
52	Fibroblast growth factor 23 is associated with fractional excretion of sodium in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 2051-2057	4.3	13
51	Lancet Countdown paper: what does it mean for nephrology?. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 4-6	4.3	2
50	The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council. <i>CKJ: Clinical Kidney Journal</i> , 2018 , 11, 437-442	4.5	0
49	ERA-EDTA invests in transformation to greener health care. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 901-903	4.3	14
48	Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis. <i>Journal of Hepatology</i> , 2018 , 68, 904-911	13.4	30
47	The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 1077-1082	4.3	3

46	Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 585-594	18.8	53
45	Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease. <i>Hepatology Research</i> , 2017 , 47, 1340-1345	5.1	21
44	Altered Protein Composition of Subcutaneous Adipose Tissue in Chronic Kidney Disease. <i>Kidney International Reports</i> , 2017 , 2, 1208-1218	4.1	10
43	Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Journal of Allergy and Clinical Immunology</i> , 2017 , 139, 1684-1687.e10	11.5	15
42	B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis. <i>CKJ: Clinical Kidney Journal</i> , 2017 , 10, 20-26	4.5	16
41	Late-onset neutropenia after rituximab in ANCA-associated vasculitis. <i>Scandinavian Journal of Rheumatology</i> , 2016 , 45, 404-7	1.9	20
40	Macrophage Migration Inhibitory Factor in Clinical Kidney Disease. <i>Frontiers in Immunology</i> , 2016 , 7, 8	8.4	16
39	Outcome and treatment of elderly patients with ANCA-associated vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 1128-35	6.9	50
38	Cholinergic anti-inflammatory pathway activity in dialysis patients: a role for neuroimmunomodulation?. <i>CKJ: Clinical Kidney Journal</i> , 2015 , 8, 599-605	4.5	8
37	Grazoprevir plus elbasvir in treatment-naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. <i>Lancet, The</i> , 2015 , 386, 1537-45	4.0	539
36	Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, 84-91	4.3	44
35	Rituximab for minimal change disease in adults: long-term follow-up. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 851-6	4.3	45
34	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis. <i>Nephron Clinical Practice</i> , 2014 , 128, 277-82		16
33	Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review. <i>American Journal of Nephrology</i> , 2014 , 39, 322-30	4.6	49
32	Macrophage migration inhibitory factor (MIF) and thyroid hormone alterations in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). <i>Molecular Medicine</i> , 2013 , 19, 109-14	6.2	8
31	Renal-limited vasculitis in children: a single-center retrospective long-term follow-up analysis. <i>Clinical Nephrology</i> , 2013 , 80, 388-94	2.1	5
30	Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 955-60	2.4	278
29	Genetically distinct subsets within ANCA-associated vasculitis. <i>New England Journal of Medicine</i> , 2012 , 367, 214-23	59.2	627

28	Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. <i>Arthritis Research and Therapy</i> , 2012 , 14, R36	5.7	53
27	Macrophage migration inhibitory factor mediates hypoxia-induced pulmonary hypertension. <i>Molecular Medicine</i> , 2012 , 18, 215-23	6.2	57
26	Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients. <i>Scandinavian Journal of Rheumatology</i> , 2012 , 41, 116-9	1.9	25
25	High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis with renal manifestations. <i>Molecular Medicine</i> , 2011 , 17, 29-35	6.2	43
24	Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. <i>American Journal of Kidney Diseases</i> , 2011 , 57, 566-74	7.4	131
23	Whole blood cytokine attenuation by cholinergic agonists ex vivo and relationship to vagus nerve activity in rheumatoid arthritis. <i>Journal of Internal Medicine</i> , 2010 , 268, 94-101	10.8	64
22	Rituximab for Multirelapsing, Steroid-Dependent or Steroid-Resistant, Minimal-Change Nephropathy: Report of Nine Adult Cases. <i>Nephrology Research & Reviews</i> , 2010 , 2, 8-11		2
21	Serum retinol-binding protein concentration and its association with components of the uremic metabolic syndrome in nondiabetic patients with chronic kidney disease stage 5. <i>American Journal of Nephrology</i> , 2009 , 29, 447-53	4.6	17
20	Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1125-30	2.4	57
19	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 719-27	4.3	35
18	Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation. <i>Molecular Medicine</i> , 2009 , 15, 70-5	6.2	43
17	High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). <i>Molecular Medicine</i> , 2008 , 14, 109-15	6.2	76
16	Gamma glutamyltranspeptidase activity and viral hepatitis in dialysis population. <i>International Journal of Artificial Organs</i> , 2007 , 30, 6-15	1.9	14
15	Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials. <i>International Journal of Artificial Organs</i> , 2007 , 30, 212-9	1.9	34
14	Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. <i>Molecular Medicine</i> , 2007 , 13, 210-5	6.2	143
13	Pegylated interferon and ribavirin in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2006 , 21, 1444-5; author reply 1445-6	4.3	8
12	Treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia--anti-viral therapy vs rituximab. <i>Rheumatology</i> , 2006 , 45, 783-4; author reply 784-5	3.9	2
11	Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia. <i>Journal of Hepatology</i> , 2006 , 44, 432-3; author reply 433	13.4	3

10	Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. <i>Journal of Viral Hepatitis</i> , 2006 , 13, 316-21	3.4	111
9	High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. <i>Hepatology</i> , 2005 , 41, 275-9	11.2	174
8	The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 3112-6	4.3	17
7	The Influence of C-Hepatitis on C-Reactive Protein in a Cohort of Brazilian Hemodialysis Patients. <i>Hemodialysis International</i> , 2004 , 8, 102-102	1.7	
6	Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. <i>Journal of Viral Hepatitis</i> , 2004 , 11, 84-7	3.4	81
5	Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. <i>Transplantation</i> , 2004 , 78, 745-50	1.8	101
4	Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. <i>Nephrology Dialysis Transplantation</i> , 2003 , 18, 1573-80	4.3	119
3	Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 701-8	3.2	117
2	Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study. <i>Journal of Viral Hepatitis</i> , 2001 , 8, 287-92	3.4	111
1	Determination of ribavirin in serum using highly selective solid-phase extraction and high-performance liquid chromatography. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 215-8	3.2	48